Pacific Biosciences of California Inc expected to post a loss of 19 cents a share - Earnings Preview

Pacific Biosciences of California

06/05/2025 22:17

Pacific Biosciences of California Inc PACB.OQ PACB.O is expected to show a fall in quarterly revenue when it reports  results on May 8 for the period ending March 31 2025

The Menlo Park California-based  company is expected to report a 10.3% decrease in revenue to $34.81 million from $38.81 million a year ago, according to the mean estimate from 13 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Pacific Biosciences of California Inc is for a loss of 19 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 9 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 0.5% in the last three months. ​

Wall Street's median 12-month price target for Pacific Biosciences of California Inc is $2.00​, above​ its last closing price of $1.11. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.21
-0.21
-0.49
Missed
-138.6
Sep. 30 2024
-0.24
-0.22
-0.22
Met
2
Jun. 30 2024
-0.24
-0.23
-0.64
Missed
-175.1​
Mar. 31 2024
-0.28
-0.28
-0.29
Missed
-5.3
​​Dec. 31 2023
-0.29
-0.29
-0.31
Missed
-8.7
Sep. 30 2023
-0.34
-0.33
-0.26
Beat
20.8​
Jun. 30 2023
-0.32
-0.32
-0.28
Beat
12.7
Mar. 31 2023
-0.33
-0.33
-0.36
Missed
-8.3

This summary was machine generated May 6 at 21:17 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)